证券代码：300759 证券简称：康龙化成 康龙化成（北京）新药技术股份有限公司投资者关系活动记录表 编号：2025-03 问：请问目前中美关税情况对公司是否有影响？ 答：截至目前，美国加征关税对公司业务产生的影响有限。公司主要 是为客户提供研发服务，CMC 涉及的商业化货物出口的业务占比较 小，目前公司并未收到客户或其他合作伙伴向公司反馈关税问题对业 务合作造成影响。对于宏观的不确定性风险，公司会密切关注相关政 策动向。地缘政治背景下，也敬请投资者注意投资风险。 问：小分子 CDMO 产能利用率和毛利率趋势？ 答：从目前公司管线看，预计公司交付项目和收入规模会进一步提 高，产能利用率和毛利率也会同比提升。 | | □特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 □业绩说明会 | | 投资者关系 活动类别 | □新闻发布会 √路演活动 | | | □现场参观 | | | □其他 | | 参与单位名称及 | | | 人员姓名 | Manulife、TruMed、SinoPac、Library Group、华凯资产管理 | | 时 间 | 年 月 日 2025 4 24 | | ...

证券代码： 002445 证券简称：中南文化 中南红文化集团股份有限公司投资者关系活动记录表 编号：2025-001 | 投资者关系活动 | □特定对象调研 □ 分析师会议 | | | --- | --- | --- | | 类别 | □ 媒体采访 √ 业绩说明会 | | | | □ 新闻发布会 □ 路演活动 | | | | 现场参观 □ | | | | 其他 （请文字说明其他活动内容） □ | | | 参与单位名称及 | 投资者网上提问 | | | 人员姓名 | | | | 时间 | 2025 年 4 月 日 (周五) 下午 15:00~16:00 | 25 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | | 采用网络远程的方式召开业绩说明会 | | | 上市公司接待人 | 1、董事长薛健 | | | 员姓名 | 2、总经理许卫国 | | | | 3、副总经理、董事会秘书蒋荣状 | | | | 4、副总经理杨宝作 | | | | 5、财务总监张弘伟 | | | | 6、独立董事许庆华 | | | 投资者关系活动 | 投资者提出的问题及公司回复情况 ...

Group 1: Company Operations and Strategy - The North American factory is progressing as planned, with preparations for production including facility renovations, equipment procurement, and personnel training [2] - The company plans to establish a wholly-owned subsidiary to enhance competitiveness in the semiconductor and high-precision manufacturing sectors, focusing on specialized equipment manufacturing and metal surface treatment [2][3] - The company is closely monitoring the robotics sector and is capable of developing related components in sync with customer needs [3] Group 2: Financial Performance and Challenges - The company reported significant losses in Q1 2025 compared to the same period last year, primarily due to increased depreciation and labor costs associated with new projects and facilities that are still ramping up production [3] - The previous year's financials were less impacted due to minimal expenses during the preparation phase of the Anhui factory and the non-completion of the MCT restructuring [3] Group 3: Future Outlook - The company aims to deepen its core business while actively developing brazing die-casting technology and expanding into the semiconductor and high-precision manufacturing industries [3]

Group 1: Product Development and Market Penetration - HSK31858 is expected to complete enrollment of over 600 participants by the second half of 2025 [3] - HSK21542 injection is anticipated to be approved for market entry in 2025 [3] - Both Kogrelitin and Clonazepam capsules have entered hundreds of secondary and higher-level hospitals [1] Group 2: Financial Performance and Projections - In Q1 2025, the company reported an 18% year-on-year increase in revenue, significantly exceeding the industry average [4] - The net profit attributable to shareholders decreased due to fluctuations in government subsidies, despite a 69% increase in net profit excluding non-recurring items [4] - R&D expenses accounted for approximately 39% of the total annual R&D budget in Q4 2024 [4] Group 3: Strategic Goals and Market Positioning - The company aims for innovative drugs to account for 40% of total sales by 2025 [3] - The focus will be on enhancing the commercialization capabilities of innovative drugs through academic promotion and brand building [6] - The company plans to expand its international market presence by selecting suitable overseas markets and product licensing [8] Group 4: R&D Investment and Pipeline - R&D investments over the past three years totaled over 2.8 billion CNY, with 2022, 2023, and 2024 investments at 958 million, 875 million, and 1 billion CNY respectively [8] - The company has 14 innovative drug projects in clinical stages, focusing on anesthesia, metabolic diseases, respiratory issues, and tumors [8] - The Protac platform has multiple drugs in early clinical stages, with ongoing IND applications [9]

证券代码：301251 证券简称：威尔高 江西威尔高电子股份有限公司 | 投资者关系活动类别 | ☐特定对象调研 ☐分析师会议 | | --- | --- | | | ☐媒体采访 业绩说明会 | | | ☐新闻发布会 ☐路演活动 | | | ☐现场参观 | | | ☐其他（请文字说明其他活动内容） | | 参与单位名称及人员姓名 | 线上参与威尔高（301251）2024年度及2025年第一季度业绩说明会 | | | 的全体投资者 | | 时间 | 2025年04月25日 15:00-16:00 | | 地点 | 价值在线（https://www.ir-online.cn/）网络互动 | | 上市公司接待人员姓名 | 总经理 陈星 | | | 董事会秘书 贾晓燕 | | | 独立董事 刘木勇 | | | 保荐代表人 曾文强 | | | 保荐代表人 帖晓东 | | | 1.请问公司对英伟达业务占比多少，本次美国的关税政策对公 司毛利率影响有多大，谢谢。 | | 投资者关系活动主要内容 | 答:尊敬的投资者,您好！4月9日，特朗普宣布除中国外，对其 | | 介绍 | 他国家的关税暂停90天，因此泰国工厂目前不受 ...

江苏捷捷微电子股份有限公司 证券代码：300623 证券简称：捷捷微电 江苏捷捷微电子股份有限公司投资者关系活动记录表 二、主要交流问题 1、公司2025年第一季度晶闸管、防护器件和MOS的营收情 况？ 答：在客户端的关心与支持下，在全体员工的共同努力下， 公司晶闸管（芯片+器件）营业收入1.32亿，较上一年度同比增 加13.54%，占公司2025年一季度主营业务收入的19.27%；公司防 护器件（芯片+器件）营业收入2.27亿，较上一年度同比增加 34.82%，占公司2025年一季度主营业务收入的32.98%；公司 MOSFET（芯片+器件）营业收入3.28亿，较上一年度同比增加 43.05%，占公司2025年一季度主营业务收入的47.75%。 编号：2025-003 | | □特定对象调研 □分析师会议 | | | | --- | --- | --- | --- | | 投资者关系活动 | □媒体采访 □业绩说明会 | | | | | □新闻发布会 □路演活动 | | | | 类别 | ☑现场参观 | | | | | ☑其他（电话会议） | | | | | 国信证券—叶子、胡剑 | | | | | 天弘基 ...

Group 1: Company Overview and Market Position - The company has successfully obtained the E-Ruling certification from U.S. Customs for its Thailand factory, enabling it to meet a significant portion of North American market demand, with North American business revenue accounting for approximately 30% of total revenue [2] - The company’s products are characterized by inelastic demand in the aftermarket, making the impact of tariff policies relatively limited [2] Group 2: Production Capacity and Investment Plans - The company is focusing on the research and mass production of harmonic reducers, which are applicable in various robotic applications, and has reached a stage for small-batch production [3] - Plans are in place to invest in a second production line in H1 2025 to prepare for future market demand growth [3] - The company is actively advancing its intelligent technology transformation projects, including a project for the annual production of 6.29 million high-end automotive bearings [3] Group 3: Global Expansion and Client Strategy - The Thailand factory has received IATF16949 certification and is undergoing a third phase of investment to expand capacity and prepare for new market demands [3] - The company aims to strengthen strategic cooperation with existing clients in the aftermarket while actively developing clients in Europe, Japan, South Korea, and emerging markets [3] - The company plans to enhance communication and collaboration with well-known manufacturers to drive growth in the original equipment manufacturer (OEM) market [3] Group 4: Risk Management and Future Outlook - The company acknowledges the uncertainty surrounding U.S. tariff policies and will closely monitor and develop strategies to seize market opportunities [2] - Future capital expenditures will be planned based on business development needs [3]

Group 1: Company Strategy and Market Position - The company aims to transition from "small oral care" to "large oral health" by expanding into smart oral care, oral beauty, and oral medical services, with a revenue growth of 35.45% in oral medical and beauty care products in 2024 [2][3] - The company employs a multi-brand strategy with core brands including "Dengkang" and "Cold Acid Spirit," targeting various consumer segments with a diverse product matrix [3] - The focus is on becoming a world-leading oral health expert, enhancing market share and competitiveness through a dedicated strategy in the oral health sector [3] Group 2: Industry Trends and Consumer Behavior - Rising awareness of oral health among consumers is driving demand for high-end and professional oral care products, with a shift towards rational and experiential consumption [4] - E-commerce channels are growing rapidly, while traditional retail is undergoing significant transformation, leading to increased competition in the market [4] Group 3: Financial Performance and Projections - The company reported a gross profit margin of 49.32% in 2024, an increase of 5.25 percentage points, driven by an optimized product mix and expansion in online sales [5] - The net profit growth of 27.07% in 2024 is attributed to increased sales scale and product upgrades [5] - Operating cash flow increased by 20.09% year-on-year, reflecting sustained growth in sales and net profit [5][8] Group 4: Shareholder Returns and Corporate Governance - The 2024 dividend plan proposes a payout of 7.5 CNY per 10 shares, with a cash dividend rate of approximately 80%, aligning with regulatory encouragement for higher investor returns [6] - The company emphasizes the protection of minority shareholders' rights and has consistently improved its dividend policy since listing [11] Group 5: Inventory and Supply Chain Management - Inventory increased by 15.64% in line with sales growth, indicating a healthy inventory turnover rate [8]

深圳市智立方自动化设备股份有限公司投资者关系活动记录表 编号：2025-001 投资者关系活动 类别 □特定对象调研 □分析师会议 □媒体采访 √业绩说明会（2024 年度业绩说明会） □新闻发布会 □路演活动 □现场参观 □其他 参与单位名称及 人员姓名 线上参与公司 2024 年度网上业绩说明会的投资者 时间 2025 年 4 月 25 日 15:00-15:30 地点 全时平台（电话会议和网络文字互动形式召开） 上市公司接待人 员姓名 董事长：邱鹏 董事会秘书兼财务负责人：廖新江 证券事务代表兼法务负责人：苏晓倩 保荐代表人：民生证券股份有限公司 秦亚中 独立董事：肖幼美、张淑钿、杜建铭 投资者关系活动 主要内容介绍 本次业绩说明会通过电话会议和网络文字互动形式对公 司 2024 年度经营、战略、财务情况进行了介绍。同时，公司 在年度报告业绩说明会上就投资者普遍关注的问题进行沟通 交流。 一、2024 年度经营、战略情况介绍 1. 主营业务介绍： 公司属于高端装备制造行业，是一家专注于半导体及工 业自动化设备的研发、生产、销售及相关技术服务的国家级高 新技术企业，为下游客户半导体工艺制程、智能制造系统、 ...

证券代码：000703 证券简称：恒逸石化 恒逸石化股份有限公司投资者关系活动记录表 编号：20250424 | | 特定对象调研 分析师会议 | | --- | --- | | 投资者关系 | 媒体采访 业绩说明会  | | 活动类别 | 新闻发布会 路演活动 | | | 现场参观 | | | 其他 （请文字说明其他活动内容） | | | 中信建投证券、申万宏源证券、天风证券、国海证券、中信 | | | 证券、国海证券资管、海通证券、中金公司、光大证券、长 | | | 江证券、富国基金、华夏基金、汇添富基金、浙商基金、汇 | | | 丰晋信基金、万家基金、泰信基金、嘉实基金、南方基金、 | | | 中银国际证券、格林基金、汇泉基金、鹏华基金、华泰柏瑞 | | | 基金、首创证券、江海证券、江信基金、南华基金、金鹰基 | | | 金、进门财经、益民基金、永赢基金、中加基金、东兴基金、 | | 参与单位名称 | 中信资本、路博迈基金、工银安盛资管、绿金投资、宁波银 | | 及人员姓名 | 行、平安资管、建信投资、农银汇理、太平洋资管、泰康资 | | | 管、上海东方证券资管、Pinpoint、北 ...